Tuesday, April 22, 2014 8:34:13 PM
I agree with you. Their estimate beat far outweighs the solvaldi price issue. Gilead is extremely undervalued at its current price. The government simply wanted an explanation; It's not like they completely halted the sale of the drug. Oh and btw Gilead DID mention the solvaldi price issue at their conference call at 4:15 today:
"The value of a cure, I tend to think, is underestimated in terms of the overall advantage that the health care system receives from it," Chief Operating Officer John Milligan said in Tuesday's conference call, detailing the long-term cost of treating patients with hepatitis C against the short-term cost of Gilead's drug regimen.
"The value of a cure, I tend to think, is underestimated in terms of the overall advantage that the health care system receives from it," Chief Operating Officer John Milligan said in Tuesday's conference call, detailing the long-term cost of treating patients with hepatitis C against the short-term cost of Gilead's drug regimen.
Recent GILD News
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 • Business Wire • 04/22/2026 08:05:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/17/2026 01:00:24 PM
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer • Business Wire • 04/17/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:41:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:40:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:12:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:08:03 PM
- PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access • Business Wire • 04/14/2026 04:00:00 PM
- Tempus AI Shares Gain After Expanded Partnership with Gilead • IH Market News • 04/10/2026 01:34:23 PM
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline • Business Wire • 04/07/2026 12:30:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/01/2026 08:34:18 PM
- Gilead Extends Tender Offer to Acquire Arcellx • Business Wire • 04/01/2026 08:13:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 09:59:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/27/2026 08:03:17 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/26/2026 10:40:06 PM
- Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases • Business Wire • 03/23/2026 10:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:01:13 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (Canada) • 03/19/2026 02:00:00 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (US) • 03/19/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 10:56:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 10:14:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/16/2026 08:06:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/16/2026 08:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 08:45:40 PM
